Hepatic Uptake of Gd-EOB-DTPA in Patients with Varying Degree of Hepatobiliary Disease
(English)Manuscript (preprint) (Other academic)
Objectives: To evaluate a method for quantifying the hepatocyte-specific uptake of GdGd-EOBDTPA in patients with hepatobiliary disease.
Methods: Gd-EOB-DTPA-enhanced liver MRI examinations of twenty-one patients with suspected hepatobiliary disease were analyzed in a novel pharmacokinetic model for quantitative assessment of hepatobiliary enhancement, using measurements in the liver and spleen. The relationship of hepatic contrast uptake rate KHep to the classification of hepatobiliary function and to the Child-Pugh and the model for end-stage liver disease (MELD) tests was studied with ordinal logistic regression and ANOVA. Comparisons were made with unadjusted liver-to-spleen ratios (LSC) and serum bilirubin. Blood clearance was evaluated via splenic measurements.
Results: KHep provided significant separation of normal hepatobiliary function from hepatobiliary disease with or without manifest biliary stasis. Goodness of fit vs. clinical classification and Child-Pugh Class was stronger for KHep than for LSC and bilirubin. The LSC and bilirubin could separate the normal group only from manifest biliary stasis. Normalization of LSC improved the results. Blood clearance was lower in hepatobiliary disease.
Conclusions: The hepatobiliary Gd-EOB-DTPA uptake test showed a significant association with the clinical grading of hepatobiliary disease and displayed significant separation of patients with affected hepatobiliary function from those with normal function.
Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid, DCE-MRI, hepatobiliary disease, pharmacokinetics, liver
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-60262OAI: oai:DiVA.org:liu-60262DiVA: diva2:355838